Rivas, Martín A. http://orcid.org/0000-0002-9603-6897
Meydan, Cem
Chin, Christopher R. http://orcid.org/0000-0002-2140-3197
Challman, Matt F.
Kim, Daleum
Bhinder, Bhavneet
Kloetgen, Andreas http://orcid.org/0000-0003-0991-4442
Viny, Aaron D. http://orcid.org/0000-0001-7039-0110
Teater, Matt R.
McNally, Dylan R.
Doane, Ashley S. http://orcid.org/0000-0002-1489-1786
Béguelin, Wendy http://orcid.org/0000-0002-4894-9229
Fernández, María Teresa Calvo
Shen, Hao
Wang, Xiang
Levine, Ross L. http://orcid.org/0000-0002-7884-1905
Chen, Zhengming
Tsirigos, Aristotelis
Elemento, Olivier
Mason, Christopher E. http://orcid.org/0000-0002-1850-1642
Melnick, Ari M. http://orcid.org/0000-0002-8074-2287
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA215317, P01CA229086-01A1, R35CA220499, P30CA008748, R35CA197594-01A1, R01CA216421, U54CA143869-05, P30CA016087, P01CA229086-01A1)
Leukemia and Lymphoma Society (LLS-SCOR7012-16, LLS-TRP6572-19, SCOR180078-02, SCOR7021-20, LLS9238-16, LLS-MCL-982)
Leukemia and Lymphoma Society
U.S. Department of Health & Human Services | NIH | National Cancer Institute
The William Raveis Charitable Fund Fellowship of the Damon Runyon Cancer Research Foundation (DRG 117-15). Evans MDS Young Investigator grant from the Edward P. Evans Foundation.
Samuel Waxman Cancer Research Foundation
The Follicular Lymphoma Consortium. The Chemotherapy Foundation.
Lymphoma Research Foundation (337387)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (5T32HL135465-3)
American Cancer Society (RSG-15-189-01-RMC)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | National Institutes of Health (UL1TR002384, R01CA194547, R01CA249054, R01AI151059, P01CA214274, R01AI125416-03, R21AI129851-02)
U.S. Department of Health & Human Services | National Institutes of Health
Leukemia and Lymphoma Society
Leukemia and Lymphoma Society
Article History
Received: 24 February 2020
Accepted: 25 October 2020
First Online: 11 January 2021
Competing interests
: A.M.M. receives research funding from Janssen Pharmaceuticals, Sanofi and Daiichi Sankyo, has consulted for Epizyme and Constellation and is on the scientific advisory board of KDAC pharmaceuticals. R.L.L. is on the supervisory board of Qiagen and was on the scientific advisory board of Loxo, Imago, Mana, Auron, C4 Therapeutics and Isoplexis, which include equity interest. R.L.L. receives research support from and consulted for Celgene and Roche and consults for Incyte, Lilly, Janssen, Astellas, Morphosys and Novartis. R.L.L. receives research support from Prelude and has received honoraria from AstraZeneca, Roche, Lilly and Amgen for invited lectures and from Gilead for grant reviews. O.E. is supported by Janssen and Eli Lilly research grants. O.E. is a scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and One Three Biotech. C.E.M. is a cofounder and board member for Biotia and Onegevity Health as well as an advisor or compensated speaker for Abbvie, Acuamark Diagnostics, ArcBio, Bio-Rad, DNA Genotek, Genialis, Genpro, Karius, Illumina, New England BioLabs, Qiagen, Whole Biome and Zymo Research. C.M. is a consultant and analyst for Onegevity Health. M.A.R., C.R.C., M.F.C., D.K., B.B., A.K., A.D.V., M.R.T., D.R.M., A.S.D., X.W., W.B., M.T.C.F., H.S., Z.C. and A.T. have no relevant competing interests to declare.